Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clonotypic peptide mass spectrometry to monitor m-protein reduction in patients with relapsed/refractory multiple myeloma from ikema Study

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLuciano Di StéfanoDKDheepak KanagavelSMSandrine Macé

Discussion

Loading...

Member takes

Overview

Exploratory analysis reveals mass spectrometry effectively tracks M-protein levels in RRMM patients, suggesting enhanced monitoring capabilities.

Key Points

  • To evaluate the feasibility of using M-inSight for monitoring M-protein reduction in patients with relapsed/refractory multiple myeloma.
  • Analyzed 392 serum samples from 89 patients in the IKEMA trial using M-inSight.
  • Identified clonotypic peptides via LC–MS/MS sequencing of baseline M-protein.
  • Tracked M-protein concentrations at specific clinical timepoints, including 12 months post-treatment.
  • Identified clonotypic peptides in 95% of baseline samples, enabling effective monitoring.
  • Achieved an average M-protein reduction of 92% in treated patients, with half exceeding 99% decrease.
  • Sustained protein depletion was noted in 22 patients even after three years post-treatment.

Cite This Study

Stéfano et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df40https://doi.org/10.1182/blood-2025-2268
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1B-241 Next-generation monitoring: M-inSightclinical application in multiple myeloma2024
  2. 2P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL2026
  3. 3Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma2025
  4. 4Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)2025
  5. 5Data from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024